Pyrimidine derivatives as POSH and POSH-AP inhibitors

A compound of the general formula I

• wherein
• R1 is alkyl, aryl, heteroaryl, —COR6, —COOR6, —NR7R8, —CONR7R8 or —NR9COR10;
• R2 is aryl or heteroaryl;
• R3 represents H or one to three radicals selected from the group consisting of lower alkyl, lower alkoxy, halogen,—NR7R8, —COOR6 and —CONR7R8;
• R4 is H, alkyl, aryl, carbocyclyl, acyl, —OH or heterocyclyl;
• R5 is H, halogen, alkyl, aryl, heteroaryl, —OR6, —SR6, —COR6, —COOR6, —NR7R8, —CONR7R8 or —NR9COR10;
• or R4 and R5 together with the carbon and nitrogen atoms to which they are attached form a 5-6 membered heterocyclic ring optionally containing a further double bond;
• R6 is H, (C2-C20) hydrocarbyl or heterocyclyl;
• R7 and R8 are each independently H, hydrocarbyl or heterocyclyl;
• or R7 and R8 together with the nitrogen atom to which they are attached form a 5-6 membered saturated heterocyclic ring, optionally containing 1 or 2 further heteroatoms selected from the group consisting of N, S and O, and wherein said further N atom is optionally substituted by lower alkyl, aralkyl, haloalkyl or hydroxyalkyl;
• R9 is H, lower alkyl or phenyl;
• R10 is aryl or heteroaryl;
• wherein said hydrocarbyl, heterocyclyl, aryl and heteroaryl is optionally substituted by one or more radicals selected from the group consisting of lower alkyl, halogen, aryl, heterocyclyl, heteroaryl, nitro, epoxy, epithio, —OR6, —SR6, —COR6, —COOR6, —NR7R8, —CONR7R8, —NR7—COR6, —SO3R6, —SO2R6, —SO2NR7R8 and —NR7SO2R6, wherein R6, R7 and R8 are as defined above;
• or an enantiomer or a pharmaceutically acceptable salt thereof.